Open access · CC-BY
via OpenAlex
Emerging Targets in Type 2 Diabetes and Diabetic Complications
Sevgican Demir, Peter P. Nawroth, Stephan Herzig, Bilgen Ekim Üstünel
Advanced Science · 2021 · ▲ 521 citations
Abstract
Type 2 diabetes is a metabolic, chronic disorder characterized by insulin resistance and elevated blood glucose levels. Although a large drug portfolio exists to keep the blood glucose levels under control, these medications are not without side effects. More importantly, once diagnosed diabetes is rarely reversible. Dysfunctions in the kidney, retina, cardiovascular system, neurons, and liver represent the common complications of diabetes, which again lack effective therapies that can reverse organ injury. Overall, the molecular mechanisms of how type 2 diabetes develops and leads to irreparable organ damage remain elusive. This review particularly focuses on novel targets that may play role in pathogenesis of type 2 diabetes. Further research on these targets may eventually pave the way to novel therapies for the treatment-or even the prevention-of type 2 diabetes along with its complications.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/advs.202100275
- Canonical
- link ↗
- Fetched
- 2026-08-05 MST
Cite this
APA
Demir, S., Nawroth, P.P., Herzig, S., & Üstünel, B.E. (2021). Emerging Targets in Type 2 Diabetes and Diabetic Complications. <em>Advanced Science</em>. https://doi.org/10.1002/advs.202100275
Vancouver
Demir S, Nawroth PP, Herzig S, Üstünel BE. Emerging Targets in Type 2 Diabetes and Diabetic Complications. Advanced Science. 2021. doi:10.1002/advs.202100275.
BibTeX
@article{sevgican2021Emergi,
title = {Emerging Targets in Type 2 Diabetes and Diabetic Complications},
author = {Sevgican Demir and Peter P. Nawroth and Stephan Herzig and Bilgen Ekim Üstünel},
journal = {Advanced Science},
year = {2021},
doi = {10.1002/advs.202100275},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cell Cycle 2011
Open access · OA
Rapamycin-induced glucose intolerance: Hunger or starvation diabetes
Liver International 2016
Open access · OA
Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?
Cell Death and Disease 2019
Open access · CC-BY
Fasting and rapamycin: diabetes versus benevolent glucose intolerance
JAMA 2025
Preprint · OA
Diagnosis and Treatment of Type 2 Diabetes in Adults
Cureus 2021
Open access · CC-BY
Intermittent Fasting: A User-Friendly Method for Type 2 Diabetes Mellitus
Diabetes 2006
Open access · OA